Combination therapy with everolimus and tacrolimus in kidney transplantation recipients: A systematic review
Publish place: Epidemiology and Health System Journal، Vol: 4، Issue: 1
Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 190
This Paper With 7 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_INJER-4-1_012
تاریخ نمایه سازی: 22 خرداد 1400
Abstract:
Background and aims: Immunosuppressive regimens are a key component for successful kidney transplantation. This systematic review aimed to assess the efficacy and safety of combination therapy of everolimus with tacrolimus in kidney transplantation recipients. Methods: Results were limited to English-language articles. Trials where recipients received another regimen were excluded. The Cochrane Central Register of Controlled Trials and MEDLINE were searched via the optimally sensitive strategies for the identification of randomized trials, combined with the following MeSH headings and text words: Everolimus, Certican, Zortress, tacrolimus, prograf, and kidney transplantation. Results: Five relevant studies of everolimus in combination with tacrolimus were identified and results of them were interpreted. Two trials investigated Fix dose of everolimus in combination with low (۱.۵-۳ mg) versus standard dose of tacrolimus (۴-۷ mg). One trial investigated variable doses of everolimus (۱.۵ mg/day or ۳ mg/day) in combination with fix dose of tacrolimusand two trials compared fix dose of everolimus versus reduction or elimination of tacrolimus. Sample size of RCTs ranged from ۲۰ to ۳۹۸ and the follow up time ranged from six to ۲۴ months. The quality score on the Jadad score was ۳ in all five trials indicating moderate quality. Conclusion: Immune suppressive regimens including everolimus in combination with tacrolimus therapy show better safety and efficacy compared with single-mode but these differences were not significant in overall studies. In general, compared with a regimen without combination of everolimus with tacrolimus, the newer immunosuppressive regimen consistently reduced the incidence of short-term biopsy-proven acute rejection. However, evidence about impact on side-effects, long term graft loss, compliance and overall health-related quality of life is limited.
Keywords:
Authors
Morteza Arab Zozani
Iranian Center of Excellence in Health Management, Tabriz University of Medical Sciences, Tabriz, I.R. Iran
Mitra Mahdavi-Mazdeh
Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran
Sayed Alireza Hosseini
Committee of clinical Research, Food and Drug Administration, Tehran, I.R. Iran
Reza Majdzadeh
School of Public Health and Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, I.R. Iran
Ali Akbari Sari
Health Management and Economics Dept., Tehran University of Medical Sciences, Tehran, I.R. Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :